摘要
目的观察紫杉醇联合卡培他滨治疗晚期胃癌的近期疗效及安全性。方法52例经病理确诊的晚期胃癌,接受紫杉醇联合卡培他滨联合化疗。紫杉醇175 mg/m2,d1;卡培他滨2 g/m2,d1～14,21 d一周期,至少化疗2周期后按WHO标准判断疗效及毒副反应。结果入组52例患者,均可评价疗效及不良反应。完全缓解0例,部分缓解22例,病情稳定30例,有效率42.3%,疾病控制率63.4%。初治组有效率57.1%,显著高于复治组25.0%(P=0.019)。主要不良反应有骨髓抑制,胃肠道反应,末梢神经毒性,多为Ⅰ～Ⅱ度,无化疗相关性死亡。结论紫杉醇联合卡培他滨治疗晚期胃癌,疗效较好,毒性低,是晚期胃癌患者的一种选择。
Objective To investigate the efficacy and toxicity of paclitaxel plus capecitabin as a chemotherapy regimen in treatment of patient with advanced gastric cancer（AGC）.Methods Fifty-two patients were diagnosed to have AGC by pathological examination.All patients received paclitaxel 175mg/m2 as a 3-h infusion on day 1,capecitabin 2.0g/m2 on day 1 to 14.Treatment was repeated every 21 days.Results All the 52 patients were evaluated for response and toxicity.The overall response rate was 42.3%,with complete and partial response rate of 0% and 42.3%,respectively.The disease control rate was 63.4%.The response rate in initial treatment group was higher than that in the retreatment group（57.1 % vs 25.0 % P=0.019）.Adverse events were generally mild,mainly including myelosuppression,gastrointestinal reaction and peripheral nerve toxicity.There was no treatment-related death.Conclusion The treatment with paclitaxel plus capecitabin shows an effective antitumor activity and favorable toxicity profile in patient with AGC.
出处
《中国肿瘤临床与康复》
2010年第2期134-136,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
紫杉醇
卡培他滨
胃肿瘤/化学疗法
Paclitaxel
Capecitabin
Stomach neoplasms/chemotherapy
